| 1 | Other/unspecified rheumatoid arthritis | FING00001126 | 80.79 |
| 2 | Allergic contact dermatitis | FING00000068 | 61.85 |
| 3 | IL2RB levels | GCST90469586 | 61.26 |
| 4 | Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers) | FING00000756 | 59.34 |
| 5 | Seropositive rheumatoid arthritis, strict definition | FING00001297 | 54.90 |
| 6 | Hyperthyroidism | GCST90319319 | 49.33 |
| 7 | Hypothyroidism (PheCode 244) | GCST90475647 | 47.84 |
| 8 | Hypothyroidism NOS (PheCode 244.4) | GCST90475653 | 46.57 |
| 9 | Myasthenia gravis | GCST90432156 | 46.36 |
| 10 | Nasal polyps (PheCode 471) | GCST90476019 | 45.92 |
| 11 | CD5 levels | GCST90468641 | 45.69 |
| 12 | Reimbursement for rheumatic diseases | FING00001247 | 45.02 |
| 13 | Preterm labour and delivery | FING00001209 | 43.47 |
| 14 | Thyroid problems | GCST90475276 | 43.17 |
| 15 | Rheumatoid arthritis | FING00001267 | 42.61 |
| 16 | Rheumatoid arthritis (PheCode 714.1) | GCST90476230 | 42.18 |
| 17 | Autoimmune diseases excluding thyroid diseases | FING00000132 | 42.07 |
| 18 | Hyperthyroidism | GCST90468136 | 41.90 |
| 19 | Autoimmune hyperthyroidism | FING00000134 | 41.43 |
| 20 | Second line medication for Crohn's disease | FING00001284 | 40.81 |
| 21 | Hypothyroidism, strict autoimmune | FING00000656 | 40.66 |
| 22 | Papulosquamous disorders | FING00001144 | 40.12 |
| 23 | Graves' disease | GCST90018627 | 40.07 |
| 24 | Disorders of the thyroid gland | FING00000463 | 39.90 |
| 25 | KLRB1 levels | GCST90469709 | 39.60 |
| 26 | Psoriatic arthritis | GCST90243956 | 39.32 |
| 27 | Lymphocyte count | GCST90018742 | 39.25 |
| 28 | Type 1 diabetes | GCST90000529 | 39.07 |
| 29 | TNFRSF8 levels | GCST90470915 | 38.90 |
| 30 | Rheumatoid arthritis and other inflammatory (PheCode 714) | GCST90476228 | 38.28 |
| 31 | CD5/TNFRSF9 ratio | GCST90313862 | 37.73 |
| 32 | Graves disease, strict definition | FING00000592 | 37.71 |
| 33 | PAG1 levels | GCST90470147 | 37.67 |
| 34 | Other (seronegative) rheumatoid arthritis, wide | FING00000917 | 37.42 |
| 35 | Myasthenia gravis | GCST90093061 | 36.60 |
| 36 | First line medication for Crohn's disease | FING00000544 | 36.08 |
| 37 | Non-cancer illness code, self-reported - hypothyroidism/myxoedema | Medical conditions | UKBB00000518 | 36.00 |
| 38 | Dissociative [conversion] disorders | FING00000468 | 35.84 |
| 39 | lymphocyte (absolute count, minimum, inv-norm transformed) | GCST90475429 | 35.70 |
| 40 | HSIL lesion of the cervix uteri | FING00000624 | 35.62 |
| 41 | Ceramide (d18:2/24:1) levels | GCST90024684 | 35.62 |
| 42 | Takes medication for Thyroid problems? | GCST90475277 | 35.55 |
| 43 | Atopic/contact dermatitis due to other or unspecified (PheCode 939) | GCST90476289 | 35.45 |
| 44 | Mean reticulocyte volume | GCST90025975 | 35.24 |
| 45 | Treatment/medication code - levothyroxine sodium | Medications | UKBB00000849 | 35.17 |
| 46 | Non-cancer illness code, self-reported - eczema/dermatitis | Medical conditions | UKBB00000509 | 35.09 |
| 47 | SKAP1 levels | GCST90470645 | 34.96 |
| 48 | Eosinophil count | GCST90025987 | 34.82 |
| 49 | Ceramide (d18:2/22:0) levels | GCST90024682 | 34.79 |
| 50 | CRTAM/FCRL6 ratio | GCST90314274 | 34.59 |
| 51 | lymphocyte (absolute count, mean, inv-norm transformed) | GCST90475426 | 34.36 |
| 52 | CD8 on Effector Memory CD8+ T cell | GCST90002056 | 34.19 |
| 53 | ITGAL levels | GCST90469637 | 34.17 |
| 54 | Blood cell traits latent factor 20 (red cell) | GCST90559262 | 33.67 |
| 55 | HSIL lesion of the cervix uteri, vagina or vulva | FING00000625 | 33.32 |
| 56 | Seropositive rheumatoid arthritis, wide | FING00001298 | 33.18 |
| 57 | Monoclonal gammopathy of undetermined significance | GCST90624745 | 33.13 |
| 58 | CD48/CRTAM ratio | GCST90313839 | 33.05 |
| 59 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Hayfever, allergic rhinitis or eczema | Medical conditions | UKBB00000100 | 32.98 |
| 60 | Polyarthropathies | FING00001180 | 32.95 |
| 61 | T1 FreeSurfer aseg Right-choroid-plexus | GCST90384170 | 32.89 |
| 62 | Lymphocyte count | GCST90002317 | 32.84 |
| 63 | Dermatitis and eczema | FING00000402 | 32.62 |
| 64 | Lymphocyte count | GCST90025984 | 32.30 |
| 65 | Hypothyroidism | endocrine/metabolic | UKBB00000335 | 32.30 |
| 66 | Right-hemisphere dorsal attention network to amygdala white-matter structural connectivity | GCST90302811 | 32.28 |
| 67 | Crohn disease (strict definition, require KELA, min 2 HDR) | FING00000366 | 32.18 |
| 68 | Psoriasis vulgaris | FING00001224 | 32.02 |
| 69 | Mean corpuscular hemoglobin concentration | GCST90002391 | 31.85 |
| 70 | Snoring | GCST009762 | 31.55 |
| 71 | Mean corpuscular hemoglobin concentration | GCST90018745 | 31.42 |
| 72 | Treatment or medication use - insulin product (UKB data field 20003_1140883066) | GCST90042226 | 31.32 |
| 73 | Late-onset myasthenia gravis | GCST90093466 | 31.16 |
| 74 | CALCOCO1/TJAP1 ratio | GCST90313611 | 31.14 |
| 75 | Hypothyroidism NOS | endocrine/metabolic | UKBB00000336 | 31.14 |
| 76 | Other hypothyroidism | Disorders of thyroid gland | UKBB00000611 | 31.08 |
| 77 | Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044) | GCST90042535 | 31.04 |
| 78 | Hypothyroidism | GCST90204167 | 31.00 |
| 79 | CD160/KLRB1 ratio | GCST90313731 | 30.81 |
| 80 | MAVS/TBL1X ratio | GCST90315399 | 30.77 |
| 81 | lymphocyte (fraction, minimum, inv-norm transformed) | GCST90475438 | 30.71 |
| 82 | Mouth/teeth dental problems - None of the above | Mouth | UKBB00000489 | 30.66 |
| 83 | Age hay fever, rhinitis or eczema diagnosed | Medical conditions | UKBB00000015 | 30.58 |
| 84 | Psoriasis vulgaris (PheCode 696.41) | GCST90476190 | 30.53 |
| 85 | FCRL6 levels | GCST90469209 | 30.47 |
| 86 | Type 1 diabetes | GCST90014023 | 30.42 |
| 87 | Mean corpuscular hemoglobin concentration | GCST90002328 | 30.39 |
| 88 | Rash and other nonspecific skin eruption (PheCode 687.1) | GCST90476167 | 30.20 |
| 89 | HEXIM1/TBL1X ratio | GCST90315053 | 30.20 |
| 90 | Type1 diabetes, definitions combined, early onset | FING00001384 | 29.94 |
| 91 | Hypothyroidism | GCST90319320 | 29.94 |
| 92 | DTI TBSS L2 External capsule L | GCST90384509 | 29.72 |
| 93 | Psoriasis (PheCode 696.4) | GCST90476187 | 29.71 |
| 94 | HLAE/IL15 ratio | GCST90315061 | 29.69 |
| 95 | Hypothyroidism | GCST90468138 | 29.68 |
| 96 | IL15/IL18BP ratio | GCST90315148 | 29.34 |
| 97 | Autoimmune diseases | FING00000131 | 29.25 |
| 98 | CDSN/WFDC12 ratio | GCST90313999 | 29.25 |
| 99 | Mean corpuscular haemoglobin concentration | Blood count | UKBB00000448 | 29.15 |
| 100 | IL2RA levels | GCST90469585 | 29.08 |
| 101 | PAFAH1B3 levels | GCST90470145 | 29.01 |
| 102 | Crohn's disease NAS | FING00000367 | 28.49 |
| 103 | lymphocyte (absolute count, maximum, inv-norm transformed) | GCST90475423 | 28.41 |
| 104 | Right-hemisphere somatomotor network to amygdala white-matter structural connectivity | GCST90302799 | 28.36 |
| 105 | GZMH levels | GCST90469425 | 28.06 |
| 106 | Graves' disease (PheCode 242.1) | GCST90475644 | 27.86 |
| 107 | Lymphocyte count | Blood count | UKBB00000411 | 27.67 |
| 108 | Thyrotoxicosis | FING00001360 | 27.61 |
| 109 | Asthma (childhood onset) | GCST007800 | 27.60 |
| 110 | Eye autorefraction and astigmatism (confirmatory factor analysis Factor 24) | GCST90309358 | 27.44 |
| 111 | Prescriptions - levothyroxine | thyroid hormone | UKBB00000687 | 27.38 |
| 112 | Prescriptions - thyroid hormone | hormone | UKBB00000705 | 27.38 |
| 113 | IL15 levels | GCST90469556 | 27.07 |
| 114 | Mean corpuscular hemoglobin concentration | GCST90002329 | 27.07 |
| 115 | Lymphocyte count | GCST004627 | 27.06 |
| 116 | Nasal polyp | FING00000858 | 27.00 |
| 117 | CRTAM/VCAM1 ratio | GCST90314281 | 26.86 |
| 118 | Paraproteinemia (PheCode 270.32) | GCST90475710 | 26.79 |
| 119 | Primary biliary cholangitis | GCST90061440 | 26.45 |
| 120 | Vanillactate levels | GCST90199978 | 26.25 |
| 121 | CC2D1A/STAMBP ratio | GCST90313664 | 26.15 |
| 122 | Lymphocyte count (UKB data field 30120) | GCST90468082 | 26.10 |
| 123 | PDCD1 levels | GCST90470181 | 26.09 |
| 124 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 78) | GCST90320641 | 26.08 |
| 125 | Coeliac disease | GCST90468120 | 25.96 |
| 126 | Disorders of orbit | FING00000449 | 25.84 |
| 127 | Rheumatoid arthritis | GCST90132223 | 25.83 |
| 128 | Allergic disease (asthma, hay fever or eczema) | GCST005038 | 25.75 |
| 129 | Regional enteritis (PheCode 555.1) | GCST90476066 | 25.72 |
| 130 | Pneumonia | GCST90018681 | 25.64 |
| 131 | Lymphoid neoplasms | GCST90624743 | 25.49 |
| 132 | Margaroylcarnitine (C17) levels | GCST90199929 | 25.48 |
| 133 | Thyrotoxicosis with diffuse goitre | FING00001361 | 25.47 |
| 134 | Type 1 diabetes | GCST90013791 | 25.42 |
| 135 | CXCL9 levels | GCST90468935 | 25.30 |
| 136 | Symptoms concerning nutrition, metabolism, and development (PheCode 1002) | GCST90475556 | 25.15 |
| 137 | Psoriasis and related disorder (PheCode 696) | GCST90476186 | 25.13 |
| 138 | Mosaic chromosomal alteration of the X chromosome | GCST90165287 | 25.08 |
| 139 | T1 FreeSurfer aseg MaskVol-to-eTIV | GCST90384192 | 24.80 |
| 140 | Eosinophill percentage (UKB data field 30210) | GCST90468069 | 24.55 |
| 141 | Thyroid peroxidase antibody positivity with euthyroid in pregnancy | GCST90435203 | 24.32 |
| 142 | DAPP1/ITGB1BP2 ratio | GCST90314388 | 24.02 |
| 143 | CD244/CRTAM ratio | GCST90313763 | 23.91 |
| 144 | Handedness (chirality/laterality) - Left-handed | Early life factors | UKBB00000302 | 23.79 |
| 145 | Type 1 diabetes, definitions combined | FING00001380 | 23.78 |
| 146 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - None of the above | Medical conditions | UKBB00000101 | 23.74 |
| 147 | Dermatitis | FING00000401 | 23.71 |
| 148 | TIGIT levels | GCST90470865 | 23.59 |
| 149 | Lymphocyte count | GCST90002388 | 23.59 |
| 150 | Dermatomycosis (PheCode 110.2) | GCST90475565 | 23.23 |
| 151 | Multiple sclerosis | GCST90475833 | 23.16 |
| 152 | Neutrophil percentage of granulocytes | GCST004623 | 23.08 |
| 153 | Seronegative rheumatoid arthritis | FING00001296 | 23.05 |
| 154 | Eczema | GCST90468126 | 23.03 |
| 155 | Avoided activities or situations because of previous stressful experience in past month | Traumatic events | UKBB00000083 | 23.01 |
| 156 | Hypothyroidism, drug reimbursement | FING00000655 | 22.91 |
| 157 | Lymphocyte count | GCST90002316 | 22.84 |
| 158 | Rheumatoid arthritis | GCST90018690 | 22.79 |
| 159 | HippSubfield lh volume GC-ML-DG-head | GCST90002679 | 22.79 |
| 160 | mean corpuscular volume (MCV, minimum, inv-norm transformed) | GCST90475474 | 22.78 |
| 161 | Eosinophill percentage | Blood count | UKBB00000207 | 22.74 |
| 162 | eosinophil (fraction, minimum, inv-norm transformed) | GCST90475303 | 22.68 |
| 163 | Eosinophil percentage of white cells | GCST004600 | 22.65 |
| 164 | ATP5IF1/METAP1D ratio | GCST90313391 | 22.47 |
| 165 | Mean corpuscular haemoglobin concentration (UKB data field 30060) | GCST90468085 | 22.41 |
| 166 | Average total household income before tax | Household | UKBB00000081 | 22.38 |
| 167 | Eosinophil percentage of granulocytes | GCST004617 | 22.28 |
| 168 | GZMA/GZMH ratio | GCST90315008 | 22.06 |
| 169 | IL2RA/NCR1 ratio | GCST90315161 | 22.05 |
| 170 | rfMRI connectivity (ICA100 edge 605) | GCST90005458 | 22.04 |
| 171 | Left-hemisphere visual network to left-hemisphere visual network white-matter structural connectivity | GCST90302648 | 21.94 |
| 172 | EDAR/LAT2 ratio | GCST90314582 | 21.93 |
| 173 | CRTAM/TNFRSF9 ratio | GCST90314280 | 21.64 |
| 174 | Dementia due to Parkinson's disease (more control exclusions) | FING00000392 | 21.53 |
| 175 | Primary biliary cholangitis | GCST003129 | 21.52 |
| 176 | Chronic obstructive pulmonary disease in current smokers | GCST90016593 | 21.44 |
| 177 | Bread type: Wholemeal/wholegrain vs white and brown (UKB data field 1448) | GCST90132968 | 21.40 |
| 178 | Noninfective enteritis and colitis | FING00000881 | 21.36 |
| 179 | PPP1R2/TBL1X ratio | GCST90315720 | 21.22 |
| 180 | mean corpuscular volume (MCV, mean, inv-norm transformed) | GCST90475470 | 21.19 |
| 181 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475450 | 21.03 |
| 182 | mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed) | GCST90475442 | 21.02 |
| 183 | SH2B3/TBL1X ratio | GCST90315841 | 20.99 |
| 184 | Eosinophill count | Blood count | UKBB00000206 | 20.98 |
| 185 | Suggestive for eosinophilic asthma | FING00001344 | 20.91 |
| 186 | lymphocyte (fraction, mean, inv-norm transformed) | GCST90475435 | 20.90 |
| 187 | Crohn's disease of small intestine | FING00000369 | 20.87 |
| 188 | CRTAM/LY9 ratio | GCST90314278 | 20.85 |
| 189 | IDP dMRI ProbtrackX L1 ifo r | GCST90004259 | 20.79 |
| 190 | GNLY levels | GCST90469372 | 20.74 |
| 191 | Inflammatory bowel disease, strict (require KELA) | FING00000675 | 20.69 |
| 192 | ANP32B levels | GCST90240176 | 20.68 |
| 193 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475446 | 20.66 |
| 194 | MZB1 levels | GCST90469987 | 20.63 |
| 195 | Follicular lymphoma, hilmo (controls excluding all cancers) | FING00000548 | 20.52 |
| 196 | Eosinophil percentage of white cells | GCST90002382 | 20.36 |
| 197 | IL1RL1 levels | GCST90469574 | 20.31 |
| 198 | Atopic dermatitis | FING00000125 | 20.21 |
| 199 | Blood cell traits latent factor 23 (white cell) | GCST90559265 | 20.08 |
| 200 | IL15/NCR1 ratio | GCST90315150 | 20.00 |
| 201 | mean corpuscular volume (MCV, maximum, inv-norm transformed) | GCST90475466 | 19.98 |
| 202 | Rheumatoid arthritis | GCST90132224 | 19.81 |
| 203 | Thyroid peroxidase antibody levels in pregnancy | GCST90435201 | 19.78 |
| 204 | SIT1 levels | GCST90470644 | 19.69 |
| 205 | Thyroid peroxidase antibody positivity in pregnancy | GCST90435202 | 19.65 |
| 206 | Eosinophill count (UKB data field 30150) | GCST90468068 | 19.56 |
| 207 | Mean reticulocyte volume | Blood count | UKBB00000451 | 19.53 |
| 208 | Rheumatoid arthritis | GCST000679 | 19.52 |
| 209 | eosinophil (fraction, mean, inv-norm transformed) | GCST90475300 | 19.45 |
| 210 | IDP dMRI TBSS L1 Posterior limb of internal capsule R | GCST90004093 | 19.39 |
| 211 | Early-onset myasthenia gravis | GCST90093465 | 19.28 |
| 212 | Solitary pulmonary nodule (PheCode 514.2) | GCST90476044 | 19.12 |
| 213 | Medication use (drugs affecting bone structure and mineralization) | GCST90018773 | 19.09 |
| 214 | Lichen ruber planus, wide definition including periferal and oral lichen planus | FING00000722 | 19.09 |
| 215 | eosinophil (fraction, maximum, inv-norm transformed) | GCST90475297 | 19.08 |
| 216 | Congenital malformations of genital organs | FING00000333 | 19.01 |
| 217 | Taking other prescription medications | Medication | UKBB00000813 | 18.92 |
| 218 | Right-hemisphere visual network to right-hemisphere dorsal attention network white-matter structural connectivity | GCST90302776 | 18.83 |
| 219 | Pollen allergy | FING00001176 | 18.73 |
| 220 | IDP dMRI TBSS ISOVF Anterior corona radiata L | GCST90004500 | 18.68 |
| 221 | ZNF830 levels | GCST90471102 | 18.65 |
| 222 | Asthma (adult onset) | GCST007799 | 18.59 |
| 223 | Poisoning by antibiotics | injuries & poisonings | UKBB00000653 | 18.51 |
| 224 | Lymphoid neoplasms (P-cell phenocluster) | GCST90624737 | 18.50 |
| 225 | Octadecenedioylcarnitine (C18:1-DC) levels | GCST90199970 | 18.46 |
| 226 | Mental and behavioural disorders due to use of other stimulants, including caffeine | FING00000811 | 18.32 |
| 227 | Ulcerative colitis | GCST90446795 | 18.28 |
| 228 | Lymphangioleiomyomatosis (sporadic) | GCST008311 | 18.24 |
| 229 | NHLRC3 levels | GCST90470046 | 18.19 |
| 230 | CD244/FCRL6 ratio | GCST90313765 | 18.16 |
| 231 | Personal history of allergy to drugs, medicaments and biologocal substances | Persons with potential health hazards related to family and personal history and certain conditions influencing health status | UKBB00000641 | 18.12 |
| 232 | Mean sphered cell volume | Blood count | UKBB00000452 | 18.12 |
| 233 | Respiratory disease (confirmatory factor analysis Factor 11) | GCST90309345 | 18.11 |
| 234 | Childhood asthma (age<16) (more control exclusions) | FING00000270 | 18.09 |
| 235 | Lymphoid neoplasms (drug group 1 phenocluster) | GCST90624740 | 18.04 |
| 236 | Cervicalgia (PheCode 761) | GCST90476267 | 18.02 |
| 237 | LTA levels | GCST90469813 | 18.02 |
| 238 | Infective dermatitis | FING00000673 | 17.99 |
| 239 | FCRL5/LY96 ratio | GCST90314803 | 17.92 |
| 240 | FUT8/TNFSF14 ratio | GCST90314895 | 17.90 |
| 241 | Other disorders of glucose regulation and pancreatic internal secretion | FING00001028 | 17.89 |
| 242 | Psoriasis | FING00001222 | 17.79 |
| 243 | PRG3 levels | GCST90470323 | 17.68 |
| 244 | TFRC levels | GCST90470840 | 17.57 |
| 245 | CLC levels | GCST90468762 | 17.41 |
| 246 | Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications | GCST90093113 | 17.41 |
| 247 | Lichen sclerosus et atrophicus | FING00000723 | 17.37 |
| 248 | Chalazion | FING00000267 | 17.32 |
| 249 | Sarcoidosis | GCST90503483 | 17.26 |
| 250 | N-acetyl-1-methylhistidine levels | GCST90200690 | 17.08 |
| 251 | Congenital malformations of ovaries, fallopian tubes and broad ligaments | FING00000337 | 17.06 |
| 252 | CXCL16 levels | GCST90468928 | 17.05 |
| 253 | Left-hemisphere dorsal attention network to amygdala white-matter structural connectivity | GCST90302706 | 17.02 |
| 254 | Chronic nephritic syndrome | FING00000295 | 17.02 |
| 255 | CD69/EDAR ratio | GCST90313875 | 16.97 |
| 256 | Leisure/social activities - None of the above | Social support | UKBB00000399 | 16.90 |
| 257 | Lymphocyte percentage | Blood count | UKBB00000412 | 16.85 |
| 258 | TPSAB1 levels | GCST90470951 | 16.77 |
| 259 | Bread type: Wholemeal or wholegrain (UKB data field 1448_3) | GCST90132966 | 16.76 |
| 260 | PLAT levels | GCST90470250 | 16.70 |
| 261 | Inflammatory bowel disease | GCST90432182 | 16.69 |
| 262 | LY6D/WFDC12 ratio | GCST90315346 | 16.67 |
| 263 | Chronic sinusitis | FING00000298 | 16.66 |
| 264 | Psoriasis | GCST90468147 | 16.66 |
| 265 | Eosinophil count | GCST90002298 | 16.59 |
| 266 | Chromatiales abundance in stool | GCST90032318 | 16.57 |
| 267 | Thyrotoxicosis with or without goiter (PheCode 242) | GCST90475643 | 16.56 |
| 268 | Eosinophil count | GCST90002381 | 16.48 |
| 269 | Lymphoid neoplasms (B-cell phenocluster) | GCST90624736 | 16.44 |
| 270 | Citrulline levels | GCST90200403 | 16.42 |
| 271 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T1 | ECGA000001 | 16.42 |
| 272 | ICD10 O60: Preterm labor and delivery | GCST90454242 | 16.33 |
| 273 | Principal component-derived dietary pattern 28 | GCST90133033 | 16.33 |
| 274 | IDP T1 SIENAX grey normalised volume | GCST90002430 | 16.30 |
| 275 | Coeliac disease | FING00000312 | 16.13 |
| 276 | EPO/TFRC ratio | GCST90314684 | 16.09 |
| 277 | MAP2K6/TBL1X ratio | GCST90315378 | 16.03 |
| 278 | Allergy/adverse effect of penicillin | injuries & poisonings | UKBB00000028 | 16.02 |
| 279 | CPXM1/HBEGF ratio | GCST90314219 | 16.01 |
| 280 | IL5RA/TNFRSF13B ratio | GCST90315164 | 15.96 |
| 281 | GZMB/IL15 ratio | GCST90315015 | 15.95 |
| 282 | ATP5IF1/LYN ratio | GCST90313389 | 15.91 |
| 283 | Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive) | GCST90132227 | 15.90 |
| 284 | CD6 levels | GCST90468644 | 15.78 |
| 285 | Left-hemisphere control network to amygdala white-matter structural connectivity | GCST90302757 | 15.73 |
| 286 | Chronic lymphocytic leukemia | GCST90624738 | 15.71 |
| 287 | Lymphocyte percentage of white cells | GCST90002389 | 15.70 |
| 288 | Cancer of urinary organs (incl. kidney and bladder) (PheCode 189) | GCST90475593 | 15.67 |
| 289 | Frailty (Factor 4 - Metabolic Problems) | GCST90624050 | 15.66 |
| 290 | Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditions | UKBB00000513 | 15.64 |
| 291 | Lichen simplex chronicus and prurigo | FING00000725 | 15.64 |
| 292 | CRTAM/ICAM3 ratio | GCST90314276 | 15.56 |
| 293 | Eosinophil count | GCST004606 | 15.52 |
| 294 | Asthma | respiratory | UKBB00000054 | 15.51 |
| 295 | Mean sphered cell volume (UKB data field 30270) | GCST90468089 | 15.50 |
| 296 | Muscular dystrophy | FING00000848 | 15.50 |
| 297 | CD160/CXCL16 ratio | GCST90313728 | 15.48 |
| 298 | Right-hemisphere control network to amygdala white-matter structural connectivity | GCST90302841 | 15.42 |
| 299 | Lymphocyte percentage (UKB data field 30180) | GCST90468083 | 15.37 |
| 300 | Asthma | GCST010042 | 15.35 |
| 301 | EDAR/ERBIN ratio | GCST90314575 | 15.27 |
| 302 | Uterine fibroids | GCST90468154 | 15.24 |
| 303 | Mean reticulocyte volume (UKB data field 30260) | GCST90468088 | 15.24 |
| 304 | Lymphocyte percentage of white cells | GCST004632 | 15.04 |
| 305 | Ulcerative colitis | GCST004133 | 15.01 |
| 306 | CD8A levels | GCST90468655 | 14.98 |
| 307 | Mean spheric corpuscular volume | GCST90002397 | 14.97 |
| 308 | Asthma | Chronic lower respiratory diseases | UKBB00000053 | 14.97 |
| 309 | Other arthritis (FG) | FING00000964 | 14.95 |
| 310 | Bread type - White | Diet | UKBB00000106 | 14.91 |
| 311 | SUGT1/TBL1X ratio | GCST90315897 | 14.78 |
| 312 | Asthma | GCST90468112 | 14.67 |
| 313 | KLRF1 levels | GCST90469712 | 14.64 |
| 314 | lymphocyte (fraction, maximum, inv-norm transformed) | GCST90475432 | 14.63 |
| 315 | Cereal intake | Diet | UKBB00000121 | 14.51 |
| 316 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Asthma | Medical conditions | UKBB00000098 | 14.41 |
| 317 | PDCD1/TNFRSF8 ratio | GCST90315610 | 14.32 |
| 318 | MS-disease / Multiple Sclerosis | FING00000839 | 14.31 |
| 319 | Handedness (chirality/laterality) - Right-handed | Early life factors | UKBB00000303 | 14.30 |
| 320 | IDP T1 SIENAX grey unnormalised volume | GCST90002431 | 14.27 |
| 321 | Bread type: White (UKB data field 1448_1) | GCST90132964 | 14.20 |
| 322 | GZMA/GZMB ratio | GCST90315007 | 14.19 |
| 323 | Open bite | FING00000903 | 14.18 |
| 324 | Vitamin B12 deficiency anaemia | FING00001441 | 14.13 |
| 325 | Sum eosinophil basophil counts | GCST004624 | 14.13 |
| 326 | SH2D1A levels | GCST90470617 | 14.12 |
| 327 | CAPG levels | GCST90468537 | 14.11 |
| 328 | Bread type: White vs wholemeal/wholegrain and brown (UKB data field 1448) | GCST90132967 | 14.10 |
| 329 | FCRL3 levels | GCST90469207 | 14.09 |
| 330 | GOPC/IRAK4 ratio | GCST90314954 | 14.06 |
| 331 | IL22 levels | GCST90469582 | 14.03 |
| 332 | Atopic dermatitis | GCST90027161 | 14.03 |
| 333 | Sarcoidosis | FING00001275 | 13.91 |
| 334 | Internal derangement of knee | injuries & poisonings | UKBB00000368 | 13.88 |
| 335 | EDAR/SNAP23 ratio | GCST90314587 | 13.82 |
| 336 | Mean reticulocyte volume | GCST90002396 | 13.81 |
| 337 | Atopic dermatitis | GCST90018564 | 13.81 |
| 338 | Dermatitis due to ingested food | FING00000403 | 13.81 |
| 339 | Lymphoid neoplasms (somatic mutation group 2 phenocluster) | GCST90624750 | 13.75 |
| 340 | Prescriptions - antispasmodic | UKBB00000666 | 13.72 |
| 341 | EBAG9/FKBP5 ratio | GCST90314564 | 13.69 |
| 342 | Other diseases of the respiratory system | FING00001011 | 13.66 |
| 343 | PPP1R14D levels | GCST90470303 | 13.62 |
| 344 | Biological Sibling: Asthma | GCST90476372 | 13.61 |
| 345 | CXCL16/NOTCH1 ratio | GCST90314339 | 13.61 |
| 346 | red cell diameter width (RDW, minimum, inv-norm transformed) | GCST90476363 | 13.60 |
| 347 | IDP dMRI TBSS OD Posterior limb of internal capsule R | GCST90004420 | 13.55 |
| 348 | GZMB levels | GCST90469424 | 13.55 |
| 349 | Dried fruit liking | GCST90094756 | 13.51 |
| 350 | Mean corpuscular volume | GCST90002392 | 13.50 |
| 351 | TSC1 levels | GCST90470972 | 13.45 |
| 352 | CD79B/TNFRSF4 ratio | GCST90313903 | 13.41 |
| 353 | Non-small cell lung cancer, squamous, excluding all cancers (controls excluding all cancers) | FING00000877 | 13.39 |
| 354 | ITGB1BP2/USP8 ratio | GCST90315223 | 13.37 |
| 355 | Mean corpuscular volume (UKB data field 30040) | GCST90468086 | 13.37 |
| 356 | Bread type - Wholemeal or wholegrain | Diet | UKBB00000107 | 13.32 |
| 357 | Cancer of bronchus; lung (PheCode 165.1) | GCST90475573 | 13.29 |
| 358 | CALCOCO1/VPS53 ratio | GCST90313612 | 13.29 |
| 359 | Cerebrospinal fluid methylmalonate (MMA) levels | GCST90318243 | 13.29 |
| 360 | CRTAM levels | GCST90468871 | 13.27 |
| 361 | NCR1 levels | GCST90470009 | 13.25 |
| 362 | Eosinophil count | GCST90002299 | 13.24 |
| 363 | VSTM2B levels | GCST90471056 | 13.23 |
| 364 | Operation code - tonsillectomy +/- adenoids | Operations | UKBB00000567 | 13.21 |
| 365 | Right-hemisphere control network to right-hemisphere control network white-matter structural connectivity | GCST90302834 | 13.13 |
| 366 | Snoring | Sleep | UKBB00000784 | 13.12 |
| 367 | CD27/NBL1 ratio | GCST90313774 | 13.12 |
| 368 | NECTIN2/NPDC1 ratio | GCST90315528 | 13.06 |
| 369 | CXCL16 levels | GCST90240524 | 13.04 |
| 370 | TP53BP1 levels | GCST90470936 | 13.02 |
| 371 | GRAP2/SRC ratio | GCST90314989 | 13.01 |
| 372 | Mean corpuscular volume | Blood count | UKBB00000449 | 13.01 |
| 373 | Lymphoid leukemia, chronic (PheCode 204.12) | GCST90475613 | 13.00 |
| 374 | ERBB4/F3 ratio | GCST90314690 | 12.99 |
| 375 | Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35) | GCST90309369 | 12.99 |
| 376 | GZMA/LTA ratio | GCST90315012 | 12.91 |
| 377 | PRG2 levels | GCST90470322 | 12.91 |
| 378 | Carboplatin drug response (IC50) | GCST90011783 | 12.89 |
| 379 | CALCOCO1/PDLIM7 ratio | GCST90313607 | 12.89 |
| 380 | Medication use (immunosuppressants) | GCST90018771 | 12.86 |
| 381 | Blood cell traits latent factor 9 (white cell) | GCST90559251 | 12.85 |
| 382 | Eosinophil count | GCST90018733 | 12.84 |
| 383 | Left-hemisphere visual network to left-hemisphere control network white-matter structural connectivity | GCST90302653 | 12.79 |
| 384 | DTI TBSS L1 Cingulum cingulate gyrus L | GCST90384463 | 12.77 |
| 385 | T1 CAT volume L VIIIa | GCST90384127 | 12.75 |
| 386 | Pulmonary fibrosis | GCST90018688 | 12.74 |
| 387 | Psoriatic arthropathies | FING00001225 | 12.72 |
| 388 | CD160 levels | GCST90468599 | 12.71 |
| 389 | CRTAM/GZMA ratio | GCST90314275 | 12.65 |
| 390 | eosinophil (absolute count, minimum, inv-norm transformed) | GCST90475294 | 12.64 |
| 391 | Rheumatoid arthritis | musculoskeletal | UKBB00000757 | 12.64 |
| 392 | DNAJC21 levels | GCST90469016 | 12.63 |
| 393 | Asthma-related infections | FING00000118 | 12.60 |
| 394 | Endometriosis | GCST90018619 | 12.57 |
| 395 | THBS2 levels | GCST90470854 | 12.56 |
| 396 | CCL8 levels | GCST90422346 | 12.50 |
| 397 | Cancer within the respiratory system (PheCode 165) | GCST90475571 | 12.49 |
| 398 | TXNL1 levels | GCST90470993 | 12.49 |
| 399 | NME3 levels | GCST90470055 | 12.47 |
| 400 | UCMA levels | GCST90243285 | 12.47 |
| 401 | Mouth/teeth dental problems - Bleeding gums | Mouth | UKBB00000485 | 12.47 |
| 402 | EDAR/TACC3 ratio | GCST90314589 | 12.43 |
| 403 | CC2D1A/STIP1 ratio | GCST90313665 | 12.43 |
| 404 | AXIN1/ITGB1BP2 ratio | GCST90313412 | 12.43 |
| 405 | Low hand grip strength (60 years and older) (EWGSOP) | GCST90007527 | 12.42 |
| 406 | Other specified disorders of external ear | FING00001104 | 12.42 |
| 407 | Percentage of monosialylation of core-fucosylated monogalactosylated structures without bisecting GlcNAc (GP41) | GCST90668485 | 12.42 |
| 408 | Low hand grip strength (60 years and older) (FNIH) | GCST90007529 | 12.36 |
| 409 | ITGB1BP2/PTPN6 ratio | GCST90315218 | 12.35 |
| 410 | CD5/IL16 ratio | GCST90313861 | 12.35 |
| 411 | Types of physical activity in last 4 weeks - None of the above | Physical activity | UKBB00000872 | 12.31 |
| 412 | Other and/or unspecified nontoxic goitre | FING00000958 | 12.23 |
| 413 | Neoplasm of uncertain behavior (PheCode 199) | GCST90475606 | 12.23 |
| 414 | CD27 levels | GCST90468615 | 12.20 |
| 415 | Asthma/COPD (KELA code 203) | FING00000121 | 12.20 |
| 416 | SLAMF8 levels | GCST90470652 | 12.19 |
| 417 | Asthma | GCST90475259 | 12.19 |
| 418 | Cataracts | GCST90018594 | 12.19 |
| 419 | eosinophil (absolute count, maximum, inv-norm transformed) | GCST90475288 | 12.18 |
| 420 | Melanoma | GCST90011809 | 12.17 |
| 421 | Phlebitis and thrombophlebitis of lower extremities (PheCode 451.2) | GCST90476004 | 12.17 |
| 422 | IDP T1 SIENAX brain-normalised volume | GCST90002434 | 12.15 |
| 423 | IL10 levels | GCST90469546 | 12.11 |
| 424 | Sicca syndrome [Sjögren] | FING00001304 | 12.11 |
| 425 | HAVCR2 levels | GCST90421515 | 12.11 |
| 426 | All pneumoniae | FING00000065 | 12.08 |
| 427 | DTI TBSS L3 Cingulum hippocampus R | GCST90384560 | 12.06 |
| 428 | Chronic lower respiratory diseases | FING00000290 | 12.03 |
| 429 | red cell diameter width (RDW, maximum, inv-norm transformed) | GCST90476355 | 12.03 |
| 430 | SIGLEC1/SSC5D ratio | GCST90315844 | 12.02 |
| 431 | BCR/FOXO1 ratio | GCST90313490 | 12.01 |
| 432 | TNFRSF17 levels | GCST90470908 | 11.99 |
| 433 | ICD10 N97.8: Female infertility of other origin | GCST90454225 | 11.97 |
| 434 | Basal cell carcinoma (MTAG) | GCST90137411 | 11.95 |
| 435 | Mineral and other dietary supplements - Glucosamine | Medication | UKBB00000473 | 11.95 |
| 436 | DTI autoptx FA slf l tract | GCST90385133 | 11.95 |
| 437 | Spleen iron concentration | GCST90101831 | 11.94 |
| 438 | Mean corpuscular volume | GCST004602 | 11.94 |
| 439 | IL32 levels | GCST90469591 | 11.94 |
| 440 | Uterine fibroids | GCST90461958 | 11.92 |
| 441 | X-21285 levels | GCST90200576 | 11.91 |
| 442 | Principal component-derived dietary pattern 42 | GCST90133047 | 11.80 |
| 443 | Psoriasis | GCST90019016 | 11.80 |
| 444 | CDC27 levels | GCST90468664 | 11.80 |
| 445 | B2M levels | GCST90468409 | 11.78 |
| 446 | eosinophil (absolute count, mean, inv-norm transformed) | GCST90475291 | 11.78 |
| 447 | CXCL5/PLXNA4 ratio | GCST90314351 | 11.74 |
| 448 | Other obstetric trauma | FING00001082 | 11.71 |
| 449 | SH3GLB2 levels | GCST90470621 | 11.61 |
| 450 | Raynauds phenomenon disease | GCST90271713 | 11.58 |
| 451 | Lung cancer | GCST004748 | 11.57 |
| 452 | Other diseases of upper respiratory tract | FING00001012 | 11.50 |
| 453 | CRTAM/PDCD1 ratio | GCST90314279 | 11.48 |
| 454 | LGALS3BP levels | GCST90469760 | 11.44 |
| 455 | Non-cancer illness code, self-reported - asthma | Medical conditions | UKBB00000506 | 11.42 |
| 456 | Mean corpuscular hemoglobin concentration | GCST004605 | 11.42 |
| 457 | Interpolated Year when non-cancer illness first diagnosed | Medical conditions | UKBB00000371 | 11.38 |
| 458 | Parkinson's disease | FING00001150 | 11.29 |
| 459 | APP/HBEGF ratio | GCST90313324 | 11.28 |
| 460 | MAVS/MED18 ratio | GCST90315389 | 11.26 |
| 461 | F5 levels | GCST90446466 | 11.20 |
| 462 | Skin cancer | GCST90475189 | 11.19 |
| 463 | Doctor diagnosed hayfever or allergic rhinitis | Medical information | UKBB00000192 | 11.16 |
| 464 | Asthma-related acute respiratory infections | FING00000117 | 11.13 |
| 465 | Systemic lupus erythematosus | GCST90011866 | 11.12 |
| 466 | MED18/TBL1X ratio | GCST90315415 | 11.12 |
| 467 | CCL19 levels | GCST90468571 | 11.11 |
| 468 | Lung adenocarcinoma | GCST004744 | 11.10 |
| 469 | DTI TBSS L2 External capsule R | GCST90384508 | 11.09 |
| 470 | Ever Smoker | FING00000522 | 11.07 |
| 471 | DTI TBSS L2 Superior longitudinal fasciculus L | GCST90384517 | 11.06 |
| 472 | TNFRSF9 levels | GCST90470916 | 11.04 |
| 473 | Ceramide (d18:2/22:0) levels | GCST90024054 | 11.03 |
| 474 | Treatment/medication code - ventolin 100micrograms inhaler | Medications | UKBB00000860 | 11.01 |
| 475 | SUMF1 levels | GCST90470783 | 10.99 |
| 476 | CRACR2A/LBR ratio | GCST90314228 | 10.98 |
| 477 | CD48/FCRL6 ratio | GCST90313840 | 10.94 |
| 478 | Dizziness and giddiness (Light-headedness and vertigo) (PheCode 386.9) | GCST90475908 | 10.87 |
| 479 | Asthma (only as main-diagnosis) (more control exclusions) | FING00000114 | 10.78 |
| 480 | TRAF2/WWP2 ratio | GCST90315943 | 10.76 |
| 481 | IFNG levels | GCST90469515 | 10.76 |
| 482 | Melanomas of skin, dx or hx (PheCode 172.1) | GCST90475577 | 10.75 |
| 483 | HMBS/PKLR ratio | GCST90315063 | 10.72 |
| 484 | Diseases of middle ear and mastoid | FING00000427 | 10.70 |
| 485 | Takes medication for Skin condition (ex. Eczema, Psoriasis)? | GCST90475275 | 10.68 |
| 486 | UGDH levels | GCST90471006 | 10.67 |
| 487 | ITGB1BP2/TIA1 ratio | GCST90315222 | 10.66 |
| 488 | GZMH/KLRD1 ratio | GCST90315016 | 10.63 |
| 489 | Lung cancer | GCST90018655 | 10.63 |
| 490 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 97) | GCST90320916 | 10.60 |
| 491 | Asthma | GCST90476024 | 10.55 |
| 492 | Basal cell carcinoma (PheCode 172.21) | GCST90475582 | 10.54 |
| 493 | AHSP/BLVRB ratio | GCST90313214 | 10.45 |
| 494 | Other circulatory problem | GCST90475217 | 10.44 |
| 495 | Asthma (more control exclusions) | FING00000113 | 10.44 |
| 496 | BAG6/BMP6 ratio | GCST90313450 | 10.32 |
| 497 | Mouth/teeth dental problems - Mouth ulcers | Mouth | UKBB00000488 | 10.29 |
| 498 | Neuroendocrine tumor and carcinoma of pancreas, excluding all cancers (controls excluding all cancers) | FING00000864 | 10.18 |
| 499 | FCRL2/SEMA7A ratio | GCST90314800 | 10.11 |
| 500 | Stearoylcarnitine (C18) levels | GCST90199743 | 10.10 |
| 501 | Hayfever | GCST90468131 | 10.09 |
| 502 | Long-standing illness, disability or infirmity | General health | UKBB00000409 | 10.09 |
| 503 | CD27/TGFBR2 ratio | GCST90313776 | 10.08 |
| 504 | EDAR/IPCEF1 ratio | GCST90314578 | 10.05 |
| 505 | IL16 levels | GCST90469557 | 10.02 |
| 506 | 3-hydroxydecanoate metabolite level | GCST90615472 | 10.01 |
| 507 | Mean corpuscular hemoglobin | GCST90002390 | 10.00 |
| 508 | CSNK1D levels | GCST90468888 | 10.00 |
| 509 | IDP T1 SIENAX brain-unnormalised volume | GCST90002435 | 9.99 |
| 510 | Operation code - spine or back surgery | Operations | UKBB00000565 | 9.98 |
| 511 | Multiple myeloma or monoclonal gammopathy of undetermined significance | GCST90624746 | 9.98 |
| 512 | DBNL/EDAR ratio | GCST90314416 | 9.97 |
| 513 | SRP14 levels | GCST90470742 | 9.95 |
| 514 | Asthma | GCST90014325 | 9.95 |
| 515 | Malignant neoplasm, excluding all cancers (controls excluding all cancers) | FING00000780 | 9.93 |
| 516 | Tobacco use disorder | mental disorders | UKBB00000824 | 9.91 |
| 517 | Strenuous sports or other exercises | GCST006100 | 9.91 |
| 518 | CALCOCO1/METAP2 ratio | GCST90313606 | 9.88 |
| 519 | Other disorders of amino-acid metabolism | FING00001014 | 9.85 |
| 520 | IFI30 levels | GCST90469509 | 9.83 |
| 521 | RBFOX3 levels | GCST90470432 | 9.81 |
| 522 | DTI autoptx L2 slf l tract | GCST90385187 | 9.75 |
| 523 | Right-hemisphere visual network to amygdala white-matter structural connectivity | GCST90302786 | 9.74 |
| 524 | BCR/ITGB1BP2 ratio | GCST90313494 | 9.74 |
| 525 | Age at onset of walking | GCST90651078 | 9.68 |
| 526 | BLNK levels | GCST90468448 | 9.66 |
| 527 | Skin cancer | GCST90475575 | 9.65 |
| 528 | mean corpuscular hemoglobin concentration (MCHC, maximum, inv-norm transformed) | GCST90475454 | 9.65 |
| 529 | Hernia abdominopelvic cavity | GCST90086087 | 9.59 |
| 530 | KLK8/WFDC12 ratio | GCST90315259 | 9.56 |
| 531 | CEACAM8/PGLYRP1 ratio | GCST90314003 | 9.55 |
| 532 | RAP1A levels | GCST90470425 | 9.53 |
| 533 | Leisure/social activities - Other group activity | Social support | UKBB00000400 | 9.52 |
| 534 | Volume of right cortical nucleus | GCST90475033 | 9.49 |
| 535 | CD74/NPDC1 ratio | GCST90313895 | 9.45 |
| 536 | DTI autoptx L1 atr l tract | GCST90385141 | 9.44 |
| 537 | mean corpuscular hemoglobin concentration (MCHC, minimum, inv-norm transformed) | GCST90475462 | 9.41 |
| 538 | Operation code - wisdom teeth surgery | Operations | UKBB00000569 | 9.36 |
| 539 | STX6 levels | GCST90470774 | 9.35 |
| 540 | IGFBP6/MFAP5 ratio | GCST90315135 | 9.33 |
| 541 | Illnesses of father - Lung cancer | Family history | UKBB00000344 | 9.29 |
| 542 | Nonspecific chest pain | circulatory system | UKBB00000527 | 9.29 |
| 543 | Iridocyclitis | FING00000696 | 9.29 |
| 544 | CXCL10 levels | GCST90468923 | 9.28 |
| 545 | Erythematosquamous dermatosis (PheCode 690) | GCST90476170 | 9.26 |
| 546 | HippSubfield lh volume CA4-head | GCST90002682 | 9.25 |
| 547 | FCRL5/ICAM3 ratio | GCST90314802 | 9.22 |
| 548 | CA1/HMBS ratio | GCST90313573 | 9.22 |
| 549 | Basal cell carcinoma | GCST90013410 | 9.21 |
| 550 | MAPRE3 levels | GCST90469859 | 9.15 |
| 551 | Seborrheic dermatitis (PheCode 690.1) | GCST90476171 | 9.07 |
| 552 | Late-onset myasthenia gravis | GCST90432158 | 9.07 |
| 553 | ITGB1BP2/WASF1 ratio | GCST90315224 | 9.06 |
| 554 | UNC5D levels | GCST90471010 | 9.04 |
| 555 | Mean corpuscular haemoglobin | Blood count | UKBB00000447 | 9.02 |
| 556 | INSL5 levels | GCST90469622 | 9.01 |
| 557 | Wheeze or whistling in the chest in last year | Breathing | UKBB00000912 | 8.97 |
| 558 | CD27/TNFRSF9 ratio | GCST90313778 | 8.96 |
| 559 | Snoring | GCST009760 | 8.95 |
| 560 | aparc-a2009s rh volume G-occipital-sup | GCST90003018 | 8.93 |
| 561 | HBEGF/PDGFA ratio | GCST90315033 | 8.92 |
| 562 | Mean corpuscular haemoglobin (UKB data field 30050) | GCST90468084 | 8.92 |
| 563 | Irregular menstrual cycle/bleeding | genitourinary | UKBB00000379 | 8.91 |
| 564 | Crohn's disease | GCST004132 | 8.91 |
| 565 | RHOC/TBCB ratio | GCST90315774 | 8.89 |
| 566 | ADAM12 levels | GCST90468216 | 8.89 |
| 567 | Never eat wheat vs no wheat restrictions (UKB data field 6144) | GCST90132932 | 8.89 |
| 568 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T2 | ECGA000002 | 8.86 |
| 569 | Glycated hemoglobin levels | GCST90002244 | 8.84 |
| 570 | ITGB7 levels | GCST90469647 | 8.84 |
| 571 | MINPP1 levels | GCST90241978 | 8.81 |
| 572 | Cerebral aneurysm, nonruptured | FING00000263 | 8.80 |
| 573 | TNFRSF13B levels | GCST90470905 | 8.79 |
| 574 | N-acetylmethionine levels | GCST90200289 | 8.77 |
| 575 | Suppurative and unspecified otitis media | FING00001346 | 8.75 |
| 576 | CD7 levels | GCST90468649 | 8.69 |
| 577 | TNF/TNFRSF1B ratio | GCST90315942 | 8.66 |
| 578 | Other non-epithelial cancer of skin (PheCode 172.2) | GCST90475580 | 8.64 |
| 579 | IDP T1 SIENAX peripheral grey normalised volume | GCST90002426 | 8.61 |
| 580 | BMP7 levels | GCST90088157 | 8.59 |
| 581 | ATF6 levels | GCST90240816 | 8.59 |
| 582 | Left-hemisphere somatomotor network to left-hemisphere control network white-matter structural connectivity | GCST90302673 | 8.58 |
| 583 | Pain in throat and chest | Symptoms and signs involving the circulatory and respiratory systems | UKBB00000625 | 8.57 |
| 584 | SNAP23/TBL1X ratio | GCST90315856 | 8.56 |
| 585 | Estradiol levels | GCST90012105 | 8.54 |
| 586 | Systemic connective tissue disorders | FING00001350 | 8.53 |
| 587 | GALNT10/SEMA7A ratio | GCST90314915 | 8.53 |
| 588 | DTI autoptx MD cgc l tract | GCST90385224 | 8.51 |
| 589 | Crohn's disease | GCST90446793 | 8.50 |
| 590 | Immature reticulocyte fraction | Blood count | UKBB00000355 | 8.48 |
| 591 | Thoracic or lumbosacral neuritis or radiculitis, unspecified (PheCode 763) | GCST90476268 | 8.48 |
| 592 | IDP dMRI ProbtrackX MD ptr r | GCST90004239 | 8.42 |
| 593 | FAM3B/FUT3_FUT5 ratio | GCST90314777 | 8.40 |
| 594 | INPP5J levels | GCST90469618 | 8.35 |
| 595 | Poultry consumption | GCST90132996 | 8.35 |
| 596 | Cancer of bladder (PheCode 189.2) | GCST90475598 | 8.34 |
| 597 | Takes medication for Chronic lung diseases including COPD, Emphysema and Bronchitis? | GCST90475273 | 8.31 |
| 598 | Red cell distribution width | GCST90025988 | 8.30 |
| 599 | CASP10 levels | GCST90468542 | 8.30 |
| 600 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475448 | 8.27 |
| 601 | Mental and behavioural disorders due to use of tobacco | Mental and behavioural disorders due to psychoactive substance use | UKBB00000460 | 8.27 |
| 602 | FCRL1/TCL1A ratio | GCST90314795 | 8.24 |
| 603 | Blood cell traits latent factor 10 (platelet) | GCST90559252 | 8.23 |
| 604 | IDP T1 FAST ROIs L cerebellum X | GCST90002587 | 8.22 |
| 605 | EDAR/F2R ratio | GCST90314577 | 8.20 |
| 606 | Job involves shift work | Employment | UKBB00000385 | 8.17 |
| 607 | Bleeding | FING00000219 | 8.15 |
| 608 | Pain type(s) experienced in last month - Pain all over the body | Pain | UKBB00000632 | 8.14 |
| 609 | FCRL6/GZMA ratio | GCST90314806 | 8.11 |
| 610 | Ulcerative colitis (strict definition, require KELA, min 2 HDR) | FING00001388 | 8.10 |
| 611 | COX5B/GFER ratio | GCST90314200 | 8.09 |
| 612 | DTI TBSS L1 Anterior corona radiata R | GCST90384450 | 8.08 |
| 613 | FCER1A levels | GCST90469198 | 8.07 |
| 614 | CAPS levels | GCST90468539 | 8.07 |
| 615 | OSMR levels | GCST90470132 | 8.07 |
| 616 | LTA4H levels | GCST90469812 | 8.03 |
| 617 | Type of accommodation lived in - A flat, maisonette or apartment | Household | UKBB00000868 | 7.99 |
| 618 | Mean corpuscular hemoglobin | GCST004630 | 7.99 |
| 619 | CA1/CA3 ratio | GCST90313572 | 7.96 |
| 620 | Pain in joint (PheCode 745) | GCST90476262 | 7.95 |
| 621 | Exotropia | GCST90572737 | 7.95 |
| 622 | mean corpuscular hemoglobin concentration (MCHC, mean, inv-norm transformed) | GCST90475458 | 7.94 |
| 623 | Disorders of plasma protein metabolism (PheCode 270.3) | GCST90475709 | 7.94 |
| 624 | Temporomandibular joint disorders, including avohilmo | FING00001355 | 7.93 |
| 625 | Urine N-acetylglutamate levels in chronic kidney disease | GCST90265569 | 7.91 |
| 626 | Avocado liking | GCST90094694 | 7.90 |
| 627 | Usual side of head for mobile phone use - Left | Electronic device use | UKBB00000889 | 7.88 |
| 628 | PDCD1/TNFRSF9 ratio | GCST90315611 | 7.87 |
| 629 | LMNB2 levels | GCST90469782 | 7.86 |
| 630 | Primary biliary cholangitis (PBC) | FING00001211 | 7.86 |
| 631 | BIN2/FYB1 ratio | GCST90313505 | 7.85 |
| 632 | Papillary adenocarcinoma of thyroid gland, excluding all cancers (controls excluding all cancers) | FING00001143 | 7.84 |
| 633 | Left-hemisphere limbic network to right-hemisphere dorsal attention network white-matter structural connectivity | GCST90302731 | 7.83 |
| 634 | IL15/KLRD1 ratio | GCST90315149 | 7.81 |
| 635 | Hair colour (natural, before greying): Red (UKB data field 1747_2) | GCST90041837 | 7.81 |
| 636 | EDAR/ITGB1BP2 ratio | GCST90314580 | 7.81 |
| 637 | Subclinical hypothyroidism in pregnancy | GCST90435197 | 7.81 |
| 638 | Cough (PheCode 512.8) | GCST90476041 | 7.80 |
| 639 | Celiac disease (PheCode 557.1) | GCST90044158 | 7.80 |
| 640 | TCL1A/TNFRSF13C ratio | GCST90315912 | 7.77 |
| 641 | Interpolated Age of participant when non-cancer illness first diagnosed | Medical conditions | UKBB00000369 | 7.76 |
| 642 | Red blood cell (erythrocyte) distribution width | Blood count | UKBB00000748 | 7.75 |
| 643 | Milk type used: Soy milk vs never have milk (UKB data field 1418) | GCST90132943 | 7.74 |
| 644 | KDM3A levels | GCST90469671 | 7.74 |
| 645 | Occupational attainment | GCST90102253 | 7.74 |
| 646 | Influenza and pneumonia | FING00000679 | 7.71 |
| 647 | Erythematous conditions (PheCode 695) | GCST90476177 | 7.71 |
| 648 | Never eat wheat vs no eggs, dairy, wheat or sugar restrictions (UKB data field 6144) | GCST90132931 | 7.70 |
| 649 | PCOLCE levels | GCST90470175 | 7.68 |
| 650 | TNFRSF13B/TNFSF13B ratio | GCST90315933 | 7.68 |
| 651 | aparc-a2009s rh area G-pariet-inf-Angular | GCST90003395 | 7.67 |
| 652 | EBAG9/TGFB1 ratio | GCST90314570 | 7.67 |
| 653 | Attendance/disability/mobility allowance - None of the above | Other sociodemographic factors | UKBB00000059 | 7.67 |
| 654 | Number in household | Household | UKBB00000530 | 7.62 |
| 655 | Principal component-derived dietary pattern 12 | GCST90133017 | 7.61 |
| 656 | MAP3K5/ZBTB16 ratio | GCST90315380 | 7.60 |
| 657 | ADH4/SCLY ratio | GCST90313195 | 7.60 |
| 658 | IDP dMRI TBSS FA Posterior limb of internal capsule R | GCST90003895 | 7.59 |
| 659 | DTI TBSS MD Posterior limb of internal capsule L | GCST90384591 | 7.57 |
| 660 | Glomerular disorders in diseases classified elsewhere | FING00000582 | 7.56 |
| 661 | Nasal polyp | Other diseases of upper respiratory tract | UKBB00000493 | 7.55 |
| 662 | Moderate-to-vigorous intensity physical activity during leisure time | GCST90104341 | 7.54 |
| 663 | aseg rh intensity Cerebellum-Cortex | GCST90003781 | 7.52 |
| 664 | DTI TBSS MD Body of corpus callosum | GCST90384575 | 7.51 |
| 665 | CD27/DLL1 ratio | GCST90313771 | 7.49 |
| 666 | CD101 levels | GCST90468596 | 7.47 |
| 667 | LBR/POLR2F ratio | GCST90315297 | 7.46 |
| 668 | IDP T1 SIENAX peripheral grey unnormalised volume | GCST90002427 | 7.46 |
| 669 | Parental longevity (combined parental age at death) | GCST006702 | 7.46 |
| 670 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T20 | ECGA000020 | 7.43 |
| 671 | CHMP1A/RHOC ratio | GCST90314053 | 7.43 |
| 672 | PFKM levels | GCST90618802 | 7.43 |
| 673 | KYNU/SCLY ratio | GCST90315265 | 7.39 |
| 674 | Qualifications - A levels/AS levels or equivalent | Education | UKBB00000727 | 7.37 |
| 675 | NPPB levels | GCST90470074 | 7.37 |
| 676 | Nasal polyps | GCST90468143 | 7.36 |
| 677 | NCAN levels | GCST90618559 | 7.36 |
| 678 | PDCD1/TNFRSF4 ratio | GCST90315609 | 7.35 |
| 679 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T228 | ECGU000228 | 7.34 |
| 680 | Dried fruit consumption | GCST90132980 | 7.33 |
| 681 | DTI TBSS L3 Superior corona radiata L | GCST90384549 | 7.32 |
| 682 | Prescriptions - tramadol | opioid analgesic,selective serotonin re-uptake inhibitor,norepinephrine re-uptake inhibitor | UKBB00000706 | 7.31 |
| 683 | Prescriptions - opioid analgesic|selective serotonin re-uptake inhibitor|norepinephrine re-uptake inhibitor | UKBB00000694 | 7.31 |
| 684 | TNFRSF11A levels | GCST90277644 | 7.30 |
| 685 | Acute upper respiratory infections | FING00000034 | 7.29 |
| 686 | Neuroticism | GCST002920 | 7.28 |
| 687 | AXL/IL18BP ratio | GCST90313420 | 7.25 |
| 688 | MAP3K5/MAVS ratio | GCST90315379 | 7.21 |
| 689 | Time spent watching television (TV) | Physical activity | UKBB00000821 | 7.21 |
| 690 | X-11550 levels | GCST90243648 | 7.21 |
| 691 | Seborrhoeic dermatitis | FING00001282 | 7.19 |
| 692 | Chronic airway obstruction | respiratory | UKBB00000135 | 7.18 |
| 693 | How many years have you or did you smoke cigarettes? (inv-normal transformed) | GCST90476390 | 7.13 |
| 694 | DTI autoptx L1 cst r tract | GCST90385148 | 7.11 |
| 695 | DTI TBSS L1 Posterior thalamic radiation L | GCST90384457 | 7.11 |
| 696 | Red cell distribution width | GCST90002369 | 7.10 |
| 697 | CCN2/HBEGF ratio | GCST90313713 | 7.08 |
| 698 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T384 | ECGU000384 | 7.07 |
| 699 | X-08402 levels | GCST90243538 | 7.06 |
| 700 | Red blood cell erythrocyte distribution width (UKB data field 30070) | GCST90468099 | 7.06 |
| 701 | CRADD/HSPA1A ratio | GCST90314239 | 7.06 |
| 702 | Qualifications - None of the above | Education | UKBB00000729 | 7.05 |
| 703 | NELL1 levels | GCST90242481 | 7.04 |
| 704 | Acute pancreatitis | FING00000027 | 7.03 |
| 705 | EFNA4/TNFRSF9 ratio | GCST90314606 | 7.03 |
| 706 | Red cell distribution width | GCST90002404 | 7.02 |
| 707 | Rosacea (PheCode 695.3) | GCST90476178 | 7.00 |
| 708 | Lifespan | GCST90551886 | 7.00 |
| 709 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475444 | 6.99 |
| 710 | HBEGF/PLXNA4 ratio | GCST90315036 | 6.98 |
| 711 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502396 | 6.95 |
| 712 | FAM13A levels | GCST90469181 | 6.95 |
| 713 | 2,3-dihydroxy-5-methylthio-4-pentenoate (dmtpa) levels | GCST90200233 | 6.94 |
| 714 | Mean platelet volume at delivery | GCST90302232 | 6.93 |
| 715 | CEP43/MPHOSPH8 ratio | GCST90314019 | 6.93 |
| 716 | DTI TBSS MD Superior corona radiata L | GCST90384597 | 6.91 |
| 717 | Principal component-derived dietary pattern 1 | GCST90133006 | 6.91 |
| 718 | SMOC2 levels | GCST90422773 | 6.91 |
| 719 | IGSF8/NECTIN2 ratio | GCST90315140 | 6.90 |
| 720 | Inflammatory bowel disease and other gasteroenteritis and colitis (PheCode 555) | GCST90476065 | 6.89 |
| 721 | Types of physical activity in last 4 weeks - Other exercises (eg: swimming, cycling, keep fit, bowling) | Physical activity | UKBB00000873 | 6.89 |
| 722 | All dysplastic lesions of the cervix uteri | FING00000060 | 6.88 |
| 723 | ENO2/RWDD1 ratio | GCST90314667 | 6.87 |
| 724 | SMPD3 levels | GCST90470685 | 6.87 |
| 725 | Hepatic cancer | GCST90018638 | 6.86 |
| 726 | SDC4/WWP2 ratio | GCST90315821 | 6.85 |
| 727 | BCL2 levels | GCST90468433 | 6.84 |
| 728 | Breast cancer | GCST90429846 | 6.83 |
| 729 | REST UKBBICA NODEamps25 0016 | GCST90385499 | 6.82 |
| 730 | CD79B/FCRL1 ratio | GCST90313899 | 6.81 |
| 731 | MCTS1 levels | GCST90469874 | 6.81 |
| 732 | NRSN1 levels | GCST90242062 | 6.80 |
| 733 | Carcinoma in situ of breast, intraductal (controls excluding all cancers) | FING00000240 | 6.80 |
| 734 | Gestational age at birth (maternal effect) | GCST90268419 | 6.79 |
| 735 | DTI autoptx L3 slf l tract | GCST90385214 | 6.78 |
| 736 | CALCOCO1/CASP3 ratio | GCST90313596 | 6.78 |
| 737 | Other arthrosis | FING00000965 | 6.77 |
| 738 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T497 | ECGA000497 | 6.77 |
| 739 | Aniseed liking | GCST90094689 | 6.76 |
| 740 | Rhodanobacter abundance in stool | GCST90032536 | 6.72 |
| 741 | Parental longevity (father's age at death) | GCST006700 | 6.71 |
| 742 | COPD/asthma/ILD related infections | FING00000353 | 6.69 |
| 743 | Type of accommodation lived in - A house or bungalow | Household | UKBB00000869 | 6.68 |
| 744 | Cervical cancer | GCST90011816 | 6.67 |
| 745 | Primary sclerosing cholangitis | GCST004030 | 6.66 |
| 746 | Omega-3 fatty acids to total fatty acids percentage | GCST90502460 | 6.66 |
| 747 | ARHGAP25/RNF41 ratio | GCST90313345 | 6.66 |
| 748 | ThalamNuclei lh volume MDl | GCST90002724 | 6.65 |
| 749 | IDP dMRI TBSS MD Posterior limb of internal capsule R | GCST90004045 | 6.62 |
| 750 | CA3/HMBS ratio | GCST90313584 | 6.60 |
| 751 | STX8 levels | GCST90470776 | 6.60 |
| 752 | Sphingomyelin_41:2_[M+H]1+ levels | GCST90060383 | 6.60 |
| 753 | Allergic rhinitis | FING00000071 | 6.60 |
| 754 | Asthma, unspecified (mode) | FING00000120 | 6.60 |
| 755 | Prostate cancer | GCST90018685 | 6.59 |
| 756 | Active to sedentary transition probability | GCST90061429 | 6.58 |
| 757 | N-acetyltaurine levels | GCST90199967 | 6.58 |
| 758 | Crohn's disease of large intestine | FING00000368 | 6.57 |
| 759 | GZMA/TNFRSF8 ratio | GCST90315014 | 6.56 |
| 760 | Smoking status (standard GWA) | GCST90267302 | 6.56 |
| 761 | CDSN/LY6D ratio | GCST90313997 | 6.55 |
| 762 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T21 | ECGA000021 | 6.52 |
| 763 | Current Smoker | FING00000371 | 6.51 |
| 764 | GDF15 levels | GCST90469321 | 6.51 |
| 765 | Ulcerative enterocolitis | FING00001391 | 6.51 |
| 766 | EZR levels | GCST90469162 | 6.49 |
| 767 | CXCL5/MESD ratio | GCST90314350 | 6.49 |
| 768 | Type 1 diabetes | GCST90432066 | 6.48 |
| 769 | GBP4 levels | GCST90469313 | 6.47 |
| 770 | Neoplasm of uncertain behavior of skin (PheCode 173) | GCST90475585 | 6.46 |
| 771 | Left-hemisphere salience/ventral attention network to amygdala white-matter structural connectivity | GCST90302724 | 6.44 |
| 772 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T4 | ECGA000004 | 6.43 |
| 773 | Diverticulitis | GCST90468125 | 6.41 |
| 774 | GPLD1 levels | GCST90086890 | 6.40 |
| 775 | Basophil count | GCST90018726 | 6.40 |
| 776 | Tooth agenesis EXCLUDE clefts and syndromes | FING00001368 | 6.39 |
| 777 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T3 | ECGA000003 | 6.38 |
| 778 | Disorders of eyelid, lacrimal system and orbit | FING00000439 | 6.37 |
| 779 | ATXN10/CASP10 ratio | GCST90313396 | 6.37 |
| 780 | DTI TBSS MD Anterior limb of internal capsule L | GCST90384589 | 6.36 |
| 781 | Secondary hypothyroidism (PheCode 244.1) | GCST90475649 | 6.35 |
| 782 | CD22/TCL1A ratio | GCST90313760 | 6.34 |
| 783 | CA2/CA3 ratio | GCST90313576 | 6.32 |
| 784 | SEMA4C levels | GCST90470572 | 6.32 |
| 785 | SPESP1 levels | GCST90470720 | 6.31 |
| 786 | LRRC37A2 levels | GCST90469802 | 6.31 |
| 787 | Biological Mother: Cancer, Skin | GCST90475487 | 6.31 |
| 788 | ICAM5 levels | GCST90469502 | 6.31 |
| 789 | Atrophic disorders of skin | FING00000129 | 6.31 |
| 790 | ENO2/PLXNA4 ratio | GCST90314665 | 6.30 |
| 791 | ICD10 N84: Polyp of female genital tract | GCST90454216 | 6.28 |
| 792 | Arachidoylcarnitine (C20) levels | GCST90200135 | 6.27 |
| 793 | Deep bite | FING00000380 | 6.26 |
| 794 | Immature reticulocyte fraction (UKB data field 30280) | GCST90468079 | 6.26 |
| 795 | Physical activity (Total log acceleration 12am-2am) | GCST90061409 | 6.23 |
| 796 | SIRT1 levels | GCST90470641 | 6.23 |
| 797 | RNF43 levels | GCST90470486 | 6.23 |
| 798 | ICD10 O14: Pre-eclampsia | GCST90454233 | 6.22 |
| 799 | CRTAM/KLRD1 ratio | GCST90314277 | 6.22 |
| 800 | COL1A1 levels | GCST90240744 | 6.19 |
| 801 | COPD-related respiratory insufficiency | FING00000352 | 6.19 |
| 802 | FCRL2/TNFRSF13B ratio | GCST90314801 | 6.18 |
| 803 | CD27/TNFRSF13B ratio | GCST90313777 | 6.17 |
| 804 | CASP8/DDX58 ratio | GCST90313651 | 6.17 |
| 805 | aseg global volume SupraTentorialNotVent | GCST90002596 | 6.17 |
| 806 | Nasal polyps | respiratory | UKBB00000494 | 6.16 |
| 807 | EBAG9/EDAR ratio | GCST90314563 | 6.14 |
| 808 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T386 | ECGU000386 | 6.13 |
| 809 | Left-hemisphere default mode network to right-hemisphere dorsal attention network white-matter structural connectivity | GCST90302762 | 6.13 |
| 810 | Other noninfective gastroenteritis and colitis | FING00001077 | 6.13 |
| 811 | Idiopathic pulmonary fibrosis | FING00000659 | 6.13 |
| 812 | EDAR/YES1 ratio | GCST90314594 | 6.12 |
| 813 | ICD10 C53: Malignant neoplasm of cervix uteri | GCST90454202 | 6.11 |
| 814 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T387 | ECGU000387 | 6.11 |
| 815 | N-acetyl-2-aminoadipate levels | GCST90200268 | 6.11 |
| 816 | Blood cell traits latent factor 17 (white cell) | GCST90559259 | 6.10 |
| 817 | CWC15 levels | GCST90468920 | 6.09 |
| 818 | PALM2 levels | GCST90470152 | 6.09 |
| 819 | Benign leiomyoma with endometriosis (controls excluding all cancers) | FING00000145 | 6.09 |
| 820 | QPCT/RNASET2 ratio | GCST90315758 | 6.08 |
| 821 | Educational attainment (confirmatory factor analysis Factor 10) | GCST90309344 | 6.08 |
| 822 | DSG2 levels | GCST90427825 | 6.06 |
| 823 | 5alpha-pregnan-3beta,20alpha-diol disulfate levels | GCST90199838 | 6.05 |
| 824 | CD160/NCR1 ratio | GCST90313732 | 6.03 |
| 825 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T383 | ECGU000383 | 6.03 |
| 826 | LAYN/TNFRSF4 ratio | GCST90315291 | 6.02 |
| 827 | Treatment speciality of consultant (recoded) - Trauma & orthopaedics | Summary Administration | UKBB00000837 | 6.01 |
| 828 | TNFRSF4 levels | GCST90470913 | 6.00 |
| 829 | Obesity related asthma | FING00000897 | 5.98 |
| 830 | FGFR4 levels | GCST90469234 | 5.98 |
| 831 | DTI TBSS MD Sagittal stratum R | GCST90384602 | 5.96 |
| 832 | CALCOCO1/IRAG2 ratio | GCST90313604 | 5.95 |
| 833 | Mucosal proctocolitis | FING00000841 | 5.95 |
| 834 | PEAR1/PECAM1 ratio | GCST90315641 | 5.94 |
| 835 | Disorders of sclera, cornea, iris and ciliary body | FING00000458 | 5.94 |
| 836 | Tyrosine levels | GCST90243425 | 5.93 |
| 837 | TNFRSF19 levels | GCST90088947 | 5.92 |
| 838 | LPCAT2/SERPINB8 ratio | GCST90315328 | 5.92 |
| 839 | GZMA/TNFRSF4 ratio | GCST90315013 | 5.91 |
| 840 | ARG1 levels | GCST90468350 | 5.91 |
| 841 | FCRL6/KLRD1 ratio | GCST90314807 | 5.91 |
| 842 | CEP43 levels | GCST90468715 | 5.90 |
| 843 | Telomere length (principal component 1) | GCST90435144 | 5.89 |
| 844 | Hypothyroidism | GCST90018642 | 5.88 |
| 845 | Prescriptions - paracetamol | antipyretic | UKBB00000696 | 5.88 |
| 846 | Prescriptions - antipyretic | UKBB00000665 | 5.88 |
| 847 | Rheumatoid arthritis and other inflammatory polyarthropathies | musculoskeletal | UKBB00000758 | 5.86 |
| 848 | Blood cell traits latent factor 12 (red cell) | GCST90559254 | 5.86 |
| 849 | Time spend outdoors in summer | Sun exposure | UKBB00000817 | 5.86 |
| 850 | Ulcerative rectosigmoiditis | FING00001394 | 5.86 |
| 851 | CALCOCO1/IKBKG ratio | GCST90313602 | 5.85 |
| 852 | Omega-3 fatty acids to total fatty acids percentage | GCST90502448 | 5.84 |
| 853 | Principal component-derived dietary pattern 29 | GCST90133034 | 5.84 |
| 854 | Principal component-derived dietary pattern 9 | GCST90133014 | 5.83 |
| 855 | Plasma ascorbic acid 2-sulfate levels in chronic kidney disease | GCST90264832 | 5.83 |
| 856 | Malignant neoplasm of breast, excluding all cancers (controls excluding all cancers) | FING00000755 | 5.83 |
| 857 | PROK1 levels | GCST90470336 | 5.82 |
| 858 | Asthma-related pneumonia | FING00000119 | 5.81 |
| 859 | Operative procedures - No procedure performed | Summary Operations | UKBB00000584 | 5.81 |
| 860 | PBLD levels | GCST90470163 | 5.80 |
| 861 | Exposure to tobacco smoke outside home | Smoking | UKBB00000229 | 5.79 |
| 862 | Number of days/week walked 10+ minutes | Physical activity | UKBB00000535 | 5.78 |
| 863 | IDP dMRI ProbtrackX L3 ptr r | GCST90004320 | 5.77 |
| 864 | TNF levels | GCST90470924 | 5.77 |
| 865 | EDAR/SERPINB1 ratio | GCST90314586 | 5.77 |
| 866 | Left-hemisphere dorsal attention network to left-hemisphere default mode network white-matter structural connectivity | GCST90302693 | 5.76 |
| 867 | XCL1 levels | GCST90471081 | 5.76 |
| 868 | Malignant neoplasm of oesophagus, excluding all cancers (controls excluding all cancers) | FING00000766 | 5.75 |
| 869 | PAXX levels | GCST90470161 | 5.74 |
| 870 | Fasting blood insulin | GCST005185 | 5.74 |
| 871 | Conjunctivitis | FING00000346 | 5.72 |
| 872 | X-21286 levels | GCST90200562 | 5.71 |
| 873 | HippSubfield lh volume Hippocampal-tail | GCST90002668 | 5.70 |
| 874 | CASP1 levels | GCST90468543 | 5.69 |
| 875 | Cooked vegetable intake | Diet | UKBB00000147 | 5.69 |
| 876 | AHCY/HSPA1A ratio | GCST90313211 | 5.66 |
| 877 | CDKN2D/ITGB1BP2 ratio | GCST90313987 | 5.65 |
| 878 | DTI TBSS L3 Superior corona radiata R | GCST90384548 | 5.65 |
| 879 | DTI autoptx L1 cst l tract | GCST90385147 | 5.65 |
| 880 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T388 | ECGU000388 | 5.64 |
| 881 | DNMBP/WWP2 ratio | GCST90314522 | 5.63 |
| 882 | TNFSF13B levels | GCST90470920 | 5.63 |
| 883 | Later onset COPD | FING00000714 | 5.62 |
| 884 | CXCL11/DKK1 ratio | GCST90314334 | 5.61 |
| 885 | Malignant neoplasm of bladder (PheCode 189.21) | GCST90475599 | 5.61 |
| 886 | MICB or MICA levels | GCST90469905 | 5.60 |
| 887 | SRC/TBL1X ratio | GCST90315884 | 5.60 |
| 888 | Blood cell traits latent factor 3 (white cell) | GCST90559245 | 5.59 |
| 889 | CLEC1B/HBEGF ratio | GCST90314092 | 5.59 |
| 890 | IDP dMRI TBSS MO Posterior limb of internal capsule R | GCST90003970 | 5.58 |
| 891 | Frontotemporal dementia | FING00000560 | 5.56 |
| 892 | GNLY/GZMA ratio | GCST90314949 | 5.55 |
| 893 | IDP dMRI TBSS L1 Posterior limb of internal capsule L | GCST90004094 | 5.54 |
| 894 | Cirrhosis | GCST90018606 | 5.53 |
| 895 | aparc-Desikan rh volume insula | GCST90002834 | 5.53 |
| 896 | Low hand grip strength (60 years and older) (EWGSOP) | GCST90007526 | 5.51 |
| 897 | aparc-pial rh area postcentral | GCST90003195 | 5.50 |
| 898 | Left-hemisphere dorsal attention network to right-hemisphere salience/ventral attention network white-matter structural connectivity | GCST90302697 | 5.50 |
| 899 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T385 | ECGU000385 | 5.49 |
| 900 | FAS levels | GCST90469192 | 5.48 |
| 901 | TNFRSF13B/TNFRSF9 ratio | GCST90315932 | 5.47 |
| 902 | CHIT1 levels | GCST90468744 | 5.46 |
| 903 | SNRPB2 levels | GCST90470697 | 5.46 |
| 904 | Brainstem global volume Medulla | GCST90002764 | 5.46 |
| 905 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T227 | ECGU000227 | 5.46 |
| 906 | Allergic asthma (mode) | FING00000066 | 5.46 |
| 907 | FCAMR levels | GCST90469196 | 5.44 |
| 908 | DTI autoptx MD fma tract | GCST90385230 | 5.41 |
| 909 | Dihomo-linoleoylcarnitine (C20:2) levels | GCST90200144 | 5.40 |
| 910 | red cell diameter width (RDW, maximum, inv-norm transformed) | GCST90476357 | 5.38 |
| 911 | CRACR2A/IRAG2 ratio | GCST90314227 | 5.37 |
| 912 | FOXO1/USP8 ratio | GCST90314879 | 5.37 |
| 913 | Cirrhosis, broad definition used in the article https://doi.org/10.1101/594523 | FING00000304 | 5.37 |
| 914 | Educational attainment | GCST002598 | 5.36 |
| 915 | aparc-a2009s rh thickness G-temporal-middle | GCST90003714 | 5.36 |
| 916 | GSTA1/PBLD ratio | GCST90314994 | 5.36 |
| 917 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 127) | GCST90320690 | 5.35 |
| 918 | Diseases of the digestive system | FING00000429 | 5.34 |
| 919 | NMNAT1 levels | GCST90470057 | 5.33 |
| 920 | GFRA2/IL12A_IL12B ratio | GCST90314925 | 5.33 |
| 921 | mean platelet volume (MPV, maximum, inv-norm transformed) | GCST90475517 | 5.33 |
| 922 | Ever had period extreme irritability | Mania | UKBB00000217 | 5.33 |
| 923 | Basophil count | GCST90002293 | 5.33 |
| 924 | MICB_MICA/TEK ratio | GCST90315446 | 5.31 |
| 925 | PSIP1 levels | GCST90470354 | 5.30 |
| 926 | aseg rh volume Amygdala | GCST90002642 | 5.30 |
| 927 | CSF2RB levels | GCST90468883 | 5.30 |
| 928 | MZB1/TNFRSF13B ratio | GCST90315509 | 5.30 |
| 929 | ACVRL1/TNFRSF9 ratio | GCST90313160 | 5.30 |
| 930 | DBNL/HSPA1A ratio | GCST90314418 | 5.30 |
| 931 | aseg global volume CC-Anterior | GCST90002611 | 5.29 |
| 932 | OCLN levels | GCST90470114 | 5.29 |
| 933 | Principal component-derived dietary pattern 20 | GCST90133025 | 5.28 |
| 934 | FCRL5/TNFRSF13B ratio | GCST90314805 | 5.28 |
| 935 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T496 | ECGA000496 | 5.28 |
| 936 | EBAG9/TBCC ratio | GCST90314568 | 5.27 |
| 937 | T1 FreeSurfer BA lh BA2 exvivo volume | GCST90385534 | 5.26 |
| 938 | Bipolar disorder | GCST003724 | 5.26 |
| 939 | JCHAIN levels | GCST90469661 | 5.25 |
| 940 | Oxalate (ethanedioate) levels | GCST90199672 | 5.24 |
| 941 | Juvenile rheumatoid arthirtis | FING00000706 | 5.24 |
| 942 | aseg lh intensity Cerebellum-Cortex | GCST90003767 | 5.24 |
| 943 | Thyroid cancer (PheCode 193) | GCST90475600 | 5.23 |
| 944 | DBI/EDAR ratio | GCST90314408 | 5.23 |
| 945 | NMT1 levels | GCST90470059 | 5.21 |
| 946 | Colitis, primary sclerosing, strict definition | FING00000313 | 5.21 |
| 947 | PPM1B levels | GCST90470296 | 5.20 |
| 948 | IL19 levels | GCST90469568 | 5.19 |
| 949 | Acquired hypothyroidism (PheCode 244.2) | GCST90475650 | 5.18 |
| 950 | Other retinal disorders | FING00001094 | 5.18 |
| 951 | DTI TBSS L3 Anterior limb of internal capsule L | GCST90384541 | 5.18 |
| 952 | PLXNB3/SNAP23 ratio | GCST90315693 | 5.18 |
| 953 | BLVRB/CA3 ratio | GCST90313523 | 5.17 |
| 954 | Sporadic miscarriage | GCST011888 | 5.17 |
| 955 | ITGB1BP2/MITD1 ratio | GCST90315214 | 5.17 |
| 956 | Malignant neoplasm of skin, excluding all cancers (controls excluding all cancers) | FING00000772 | 5.16 |
| 957 | FOLH1 levels | GCST90427192 | 5.16 |
| 958 | Crohn's disease | GCST90475318 | 5.15 |
| 959 | Cervical cancer | GCST90018597 | 5.15 |
| 960 | PDLIM7/PLA2G4A ratio | GCST90315637 | 5.15 |
| 961 | Urine glucosaminate levels in chronic kidney disease | GCST90265179 | 5.14 |
| 962 | FLT3/FLT3LG ratio | GCST90314859 | 5.13 |
| 963 | NOTCH1/SEMA7A ratio | GCST90315545 | 5.12 |
| 964 | Polyarthrosis | FING00001181 | 5.12 |
| 965 | Temporomandibular joint disorders | FING00001354 | 5.12 |
| 966 | Principal component-derived dietary pattern 26 | GCST90133031 | 5.12 |
| 967 | Enthesopathies of lower limb, excluding foot | FING00000509 | 5.11 |
| 968 | Flat foot [pes planus] (acquired) | FING00000545 | 5.10 |
| 969 | Principal component-derived dietary pattern 43 | GCST90133048 | 5.09 |
| 970 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 60) | GCST90320879 | 5.09 |
| 971 | Cancer | GCST90086052 | 5.08 |
| 972 | CNTNAP4 levels | GCST90468809 | 5.07 |
| 973 | APBB1IP/POLR2F ratio | GCST90313300 | 5.06 |
| 974 | LTA/LTBR ratio | GCST90315336 | 5.04 |
| 975 | ICAM3/LY9 ratio | GCST90315121 | 5.03 |
| 976 | aparc-pial lh area lateralorbitofrontal | GCST90003152 | 5.03 |
| 977 | Treatment/medication code - lansoprazole | Medications | UKBB00000848 | 5.03 |
| 978 | neutrophil (fraction, mean, inv-norm transformed) | GCST90475538 | 5.02 |
| 979 | CXCL11/ITGB1BP2 ratio | GCST90314335 | 5.02 |
| 980 | DTI autoptx L1 slf r tract | GCST90385161 | 5.02 |
| 981 | IDP T1 FIRST right caudate volume | GCST90002439 | 5.02 |
| 982 | Cereal consumption (bowls per week) (UKB data field 1458) | GCST90132982 | 5.00 |
| 983 | Restless legs syndrome | GCST90435387 | 4.99 |
| 984 | FUT3 or FUT5 levels | GCST90469280 | 4.97 |
| 985 | Other systemic involvement of connective tissue (FG) | FING00001116 | 4.96 |
| 986 | EDAR/EGF ratio | GCST90314573 | 4.96 |
| 987 | Dry age-related macular degeneration (includes geographic atrophy) | FING00000480 | 4.95 |
| 988 | Sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0) levels | GCST90200017 | 4.93 |
| 989 | Staphylococcus A fleurettii abundance in stool | GCST90032564 | 4.92 |
| 990 | Principal component-derived dietary pattern 21 | GCST90133026 | 4.92 |
| 991 | DAB2/ERBIN ratio | GCST90314361 | 4.92 |
| 992 | AMOTL2 levels | GCST90468294 | 4.92 |
| 993 | GCHFR levels | GCST90469317 | 4.91 |
| 994 | Eicosenoylcarnitine (C20:1) levels | GCST90200148 | 4.91 |
| 995 | Allergic conjunctivitis | FING00000067 | 4.91 |
| 996 | CDH17/SPINT1 ratio | GCST90313944 | 4.90 |
| 997 | CD48 levels | GCST90468635 | 4.90 |
| 998 | Smoking status (weighted GWA) | GCST90267303 | 4.90 |
| 999 | rfMRI connectivity (ICA100 edge 495) | GCST90005348 | 4.88 |
| 1000 | Emphysema (PheCode 496.1) | GCST90476028 | 4.87 |